Patient with hypertriglyceridemia, type 2 diabetes, and chronic kidney disease treated with atorvastatin and omega-3 fatty acid ethyl esters

Open Cardiovascular Medicine Journal

Volumn 6, Issue 1, 2012, Pages 122-125

  Athyros, Vasilios G ^a   Mikhailidis, Dimitri P ^b  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Hypertriglyceridemia; Omega 3 fatty acid ethyl esters; Statin; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; GEMFIBROZIL; INSULIN; LIPID; OMEGA 3 ACID ETHYL ESTER; QUINAPRIL; SIMVASTATIN; SITAGLIPTIN;

AGED; ARTICLE; CASE REPORT; CHRONIC KIDNEY DISEASE; DIABETES CONTROL; DIABETIC NEPHROPATHY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIFESTYLE MODIFICATION; LIPID BLOOD LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RHABDOMYOLYSIS; TREATMENT RESPONSE;

EID: 84871014821     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401206010122     Document Type: Article

References (30)

1. Athyros VG, Mitsiou EK, Tziomalos K, Karagiannis A, Mikhailidis DP. Impact of managing atherogenic dyslipidemia on cardiovascular outcome across different stages of diabetic nephropathy. Expert Opin Pharmacother 2010; 11: 723-30.
2. Athyros VG, Papageorgiou AA, Elisaf M, Mikhailidis DP; GREACE Study Collaborative. Group. Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin 2003; 19: 615-7.
3. Athyros VG, Karagiannis A, Kakafika A, Elisaf M, Mikhailidis DP. Statins and renal function. Is the compound and dose making a difference? Nephrol Dial Transplant 2007; 22: 963-4.
4. Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS. The effect of cholesterol-lowering treatment on renal function. Am J Kidney Dis 2006; 47: 561.
5. Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Omega-3 fatty acids: how can they be used in secondary prevention? Curr Atheroscler Rep 2008; 10: 510-7.
6. Schaefer EJ, Lichtenstein AH, Lamon-Fava S, et al. Effects of National Cholesterol Education Program Step 2 diets relatively high or relatively low in fish-derived fatty acids on plasma lipoproteins in middle-aged and elderly subjects. Am J Clin Nutr 1996; 63: 234-41.
7. Sun Z, Welty FK, Dolnikowski GG, Lichtenstein AH, Schaefer EJ. Effects of a National Cholesterol Education Program Step II Diet on apolipoprotein A-IV metabolism within triacylglycerol-rich lipoproteins and plasma. Am J Clin Nutr 2001; 74: 308-14.
8. Boucher BJ. Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use. But what about the amiodarone? Diabet Med 2009; 26: 192-3.
9. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 2004; 109: III 50-7.
10. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Stage of chronic kidney disease and severity of coronary heart disease manifestation. Expert Opin Pharmacother 2012; 13: 457-60.
11. Athyros VG, Hatzitolios AI, Karagiannis A, et al. For the imperative collaborative group. improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. the imperative renal analysis. Arch Med Sci 2011; 7: 984-92.
12. Athyros VG, Karagiannis A, Ganotakis ES, et al; Assessing the treatment effect in metabolic syndrome without perceptible diabetes (ATTEMPT) collaborative group. association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study. Curr Med Res Opin 2011; 27: 1659-68.
13. Efstratiadis G, Tziomalos K, Mikhailidis DP, Athyros VG, Hatzitolios A. Atherogenesis in renal patients: a model of vascular disease? Curr Vasc Pharmacol 2008; 6: 93-107.
14. Athyros VG, Kakafika AI, Papageorgiou AA, et al. Statin-induced increase in HDL-C and renal function in coronary heart disease patients. Open Cardiovasc Med J 2007; 1: 8-14.
15. Athyros VG, Karagiannis A, Katsiki N, Mikhailidis DP. Statins in patients with renal dysfunction. Am J Cardiol 2012; 109: 1537.
16. Athyros VG, Katsiki N, Karagiannis A, Mikhailidis DP. Should chronic kidney disease be considered as a coronary heart disease equivalent? Curr Vasc Pharmacol 2012; 10: 374-7.
17. Tziomalos K, Ganotakis ES, Gazi IF, Nair DR, Mikhailidis DP. Kidney Function and estimated vascular risk in patients with primary dyslipidemia. Open Cardiovasc Med J 2009; 3: 57-68.
18. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment. Open Cardiovasc Med J 2011; 5: 24-34.
19. Athyros VG, Karagiannis A, Liberopoulos EN, Elisaf M, Mikhailidis DP. Statin treatment may be beneficial to both the kidneys and the heart. Perit Dial Int 2007; 27: 215-6.
20. Mitsiou EK, Athyros VG, Karagiannis A, Mikhailidis DP. Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes? Open Cardiovasc Med J 2012; 6: 28-32.
21. Fabbian F, Pala M, Giorgi A De, et al. Clinical features of cardiorenal syndrome in a cohort of consecutive patients admitted to an internal medicine ward. Open Cardiovasc Med J 2011; 5: 220-5.
22. Athyros VG, Katsiki N, Tziomalos K, Karagiannis A. Preventing cardio-renal syndrome rather than treating it: could statins play a role? Open Cardiovasc Med J 2011; 5: 226-30.
23. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769-818.
24. Diabetes and Chronic Kidney Disease Work Group. KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease. Am J Kidney Dis 2007; 49: S13-9.
25. Athyros VG, Mikhailidis DP, Papageorgiou AA, et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57: 728-34.
26. Navaneethan SD, Pansini F, Perkovic V, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; CD007784.
27. Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest 2002; 32: 429-36.
28. Durrington PN, Bhatnagar D, Mackness MI, et al. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart 2001; 85: 544-8.
29. Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes 2002; 51: 2377-86.
30. Davidson MH, Stein EA, Bays HE, et al Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther 2007; 29: 1354-67.